Hybrid dual aromatase-steroid sulfatase inhibitors with exquisite picomolar inhibitory activity

L. W. Lawrence Woo, Christian Bubert, Atul Purohit, Barry V. L. Potter

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Single agents against multiple drug targets are highly topical. Hormone-dependent breast cancer (HDBC) may be more effectively treated by dual inhibition of aromatase and steroid sulfatase (STS), and several dual aromatase-sulfatase inhibitors (DASIs) have been recently reported. The best compounds from two leading classes of DASI, 3 and 9, are low nanomolar inhibitors. In search of a novel class of DASI, core motifs of two leading classes were combined to give a series of hybrid structures, with several compounds showing markedly improved dual inhibitory activities in the picomolar range in JEG-3 cells. Thus, DASIs 14 (IC50: aromatase, 15 pM; STS, 830 pM) and 15 (IC50: aromatase, 18 pM; STS, 130 pM) are the first examples of an exceptional new class of highly potent dual inhibitor that should encourage further development toward multitargeted therapeutic intervention in HDBC.
Original languageEnglish
Pages (from-to)243-247
JournalACS Medicinal Chemistry Letters
Volume2
Issue number3
DOIs
Publication statusPublished - Mar 2011

Fingerprint

Steryl-Sulfatase
Sulfatases
Aromatase Inhibitors
Aromatase
Inhibitory Concentration 50
Hormones
Breast Neoplasms
Pharmaceutical Preparations

Keywords

  • sulfatase
  • aromatase
  • hybrid
  • dual inhibitors
  • cancer

Cite this

Hybrid dual aromatase-steroid sulfatase inhibitors with exquisite picomolar inhibitory activity. / Woo, L. W. Lawrence; Bubert, Christian; Purohit, Atul; Potter, Barry V. L.

In: ACS Medicinal Chemistry Letters, Vol. 2, No. 3, 03.2011, p. 243-247.

Research output: Contribution to journalArticle

Woo, L. W. Lawrence ; Bubert, Christian ; Purohit, Atul ; Potter, Barry V. L. / Hybrid dual aromatase-steroid sulfatase inhibitors with exquisite picomolar inhibitory activity. In: ACS Medicinal Chemistry Letters. 2011 ; Vol. 2, No. 3. pp. 243-247.
@article{af42f6d2f81840abb1278c948310eb15,
title = "Hybrid dual aromatase-steroid sulfatase inhibitors with exquisite picomolar inhibitory activity",
abstract = "Single agents against multiple drug targets are highly topical. Hormone-dependent breast cancer (HDBC) may be more effectively treated by dual inhibition of aromatase and steroid sulfatase (STS), and several dual aromatase-sulfatase inhibitors (DASIs) have been recently reported. The best compounds from two leading classes of DASI, 3 and 9, are low nanomolar inhibitors. In search of a novel class of DASI, core motifs of two leading classes were combined to give a series of hybrid structures, with several compounds showing markedly improved dual inhibitory activities in the picomolar range in JEG-3 cells. Thus, DASIs 14 (IC50: aromatase, 15 pM; STS, 830 pM) and 15 (IC50: aromatase, 18 pM; STS, 130 pM) are the first examples of an exceptional new class of highly potent dual inhibitor that should encourage further development toward multitargeted therapeutic intervention in HDBC.",
keywords = "sulfatase, aromatase, hybrid, dual inhibitors, cancer",
author = "Woo, {L. W. Lawrence} and Christian Bubert and Atul Purohit and Potter, {Barry V. L.}",
year = "2011",
month = "3",
doi = "10.1021/ml100273k",
language = "English",
volume = "2",
pages = "243--247",
journal = "ACS Medicinal Chemistry Letters",
issn = "1948-5875",
publisher = "American Chemical Society",
number = "3",

}

TY - JOUR

T1 - Hybrid dual aromatase-steroid sulfatase inhibitors with exquisite picomolar inhibitory activity

AU - Woo, L. W. Lawrence

AU - Bubert, Christian

AU - Purohit, Atul

AU - Potter, Barry V. L.

PY - 2011/3

Y1 - 2011/3

N2 - Single agents against multiple drug targets are highly topical. Hormone-dependent breast cancer (HDBC) may be more effectively treated by dual inhibition of aromatase and steroid sulfatase (STS), and several dual aromatase-sulfatase inhibitors (DASIs) have been recently reported. The best compounds from two leading classes of DASI, 3 and 9, are low nanomolar inhibitors. In search of a novel class of DASI, core motifs of two leading classes were combined to give a series of hybrid structures, with several compounds showing markedly improved dual inhibitory activities in the picomolar range in JEG-3 cells. Thus, DASIs 14 (IC50: aromatase, 15 pM; STS, 830 pM) and 15 (IC50: aromatase, 18 pM; STS, 130 pM) are the first examples of an exceptional new class of highly potent dual inhibitor that should encourage further development toward multitargeted therapeutic intervention in HDBC.

AB - Single agents against multiple drug targets are highly topical. Hormone-dependent breast cancer (HDBC) may be more effectively treated by dual inhibition of aromatase and steroid sulfatase (STS), and several dual aromatase-sulfatase inhibitors (DASIs) have been recently reported. The best compounds from two leading classes of DASI, 3 and 9, are low nanomolar inhibitors. In search of a novel class of DASI, core motifs of two leading classes were combined to give a series of hybrid structures, with several compounds showing markedly improved dual inhibitory activities in the picomolar range in JEG-3 cells. Thus, DASIs 14 (IC50: aromatase, 15 pM; STS, 830 pM) and 15 (IC50: aromatase, 18 pM; STS, 130 pM) are the first examples of an exceptional new class of highly potent dual inhibitor that should encourage further development toward multitargeted therapeutic intervention in HDBC.

KW - sulfatase

KW - aromatase

KW - hybrid

KW - dual inhibitors

KW - cancer

UR - http://www.scopus.com/inward/record.url?scp=79952648555&partnerID=8YFLogxK

UR - http://dx.doi.org/10.1021/ml100273k

U2 - 10.1021/ml100273k

DO - 10.1021/ml100273k

M3 - Article

VL - 2

SP - 243

EP - 247

JO - ACS Medicinal Chemistry Letters

JF - ACS Medicinal Chemistry Letters

SN - 1948-5875

IS - 3

ER -